Literature DB >> 2855415

The cell interaction sites of fibronectin in tumour metastasis.

M J Humphries1, Y Yasuda, K Olden, K M Yamada.   

Abstract

Adhesion to specific extracellular matrix molecules appears to be an important prerequisite for successful target organ colonization by metastasizing tumour cells. Interference in the adhesive function of malignant cells with antiadhesive agents is therefore one potential approach for preventing metastasis. Recently, synthetic peptides taken from the cell interaction sites of fibronectin have been characterized as inhibitors of cellular adhesion in vitro. Using these antiadhesive probes we have examined the role of cell adhesion to fibronectin in tumour metastasis using the B16-F10 murine melanoma model system. Two sequences from the IIICS cell-binding domain, the 25-mer CS1 peptide and the tetrapeptide Arg-Glu-Asp-Val (REDV), had no detectable activity, but the pentapeptide Gly-Arg-Gly-Asp-Ser (GRGDS), an active sequence from the central cell-binding domain, exhibited potent, dose-dependent inhibition, indicating a role for this cell recognition determinant in tumour metastasis. Under appropriate conditions GRGDS treatment afforded remarkable protection to the host; mice injected with melanoma cells and peptide were still alive 15 months after injection whereas mice injected with melanoma cells alone died within six weeks. Kinetic analyses of the retention of tumour cells in the lungs and of the vascular clearance rate of labelled GRGDS predict an early time frame of activity for the peptide. From the results of a variety of in vitro invasion and migration assays it appears that GRGDS may interfere with multiple, fibronectin-mediated adhesive and migratory events at different points of the metastatic cascade. In preliminary studies designed to optimize the therapeutic usefulness of GRGDS-like agents, peptide conjugates have been found to possess enhanced antiadhesive activity as well as an extended vascular clearance rate. In the future, therefore, these or related peptide derivatives may be potentially useful agents for the prevention of tumour metastasis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2855415     DOI: 10.1002/9780470513736.ch5

Source DB:  PubMed          Journal:  Ciba Found Symp        ISSN: 0300-5208


  5 in total

Review 1.  VLA-4 and lymphocyte trafficking in immune-inflammatory states: novel therapeutic approaches in allograft arteriopathy.

Authors:  S Molossi; M Rabinovitch
Journal:  Springer Semin Immunopathol       Date:  1995

2.  The monoclonal antibody SM5-1 recognizes a fibronectin variant which is widely expressed in melanoma.

Authors:  Uwe Trefzer; Yingwen Chen; Gunda Herberth; Maja Ann Hofmann; Felix Kiecker; Yajun Guo; Wolfram Sterry
Journal:  BMC Cancer       Date:  2006-01-11       Impact factor: 4.430

3.  Cellular fibronectin concentration in the plasma of patients with malignant and benign diseases: a comparison with CA 19-9 and CEA.

Authors:  C Haglund; S Ylätupa; P Mertaniemi; P Partanen
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  Gene expression profiling identifies Fibronectin 1 and CXCL9 as candidate biomarkers for breast cancer screening.

Authors:  E Ruiz-Garcia; V Scott; C Machavoine; J M Bidart; L Lacroix; S Delaloge; F Andre
Journal:  Br J Cancer       Date:  2010-01-12       Impact factor: 7.640

Review 5.  Regulation of tissue fibrosis by the biomechanical environment.

Authors:  Wayne Carver; Edie C Goldsmith
Journal:  Biomed Res Int       Date:  2013-05-28       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.